Novozymes AS
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as protein solutions and … Read more
Novozymes AS (NVZMY) - Net Assets
Latest net assets as of September 2025: $10.78 Billion USD
Based on the latest financial reports, Novozymes AS (NVZMY) has net assets worth $10.78 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($16.36 Billion) and total liabilities ($5.58 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.78 Billion |
| % of Total Assets | 65.91% |
| Annual Growth Rate | 4.49% |
| 5-Year Change | -0.6% |
| 10-Year Change | -3.6% |
| Growth Volatility | 12.71 |
Novozymes AS - Net Assets Trend (2002–2024)
This chart illustrates how Novozymes AS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Novozymes AS (2002–2024)
The table below shows the annual net assets of Novozymes AS from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $11.18 Billion | -22.12% |
| 2023-12-31 | $14.35 Billion | +0.86% |
| 2022-12-31 | $14.23 Billion | +16.57% |
| 2021-12-31 | $12.21 Billion | +8.56% |
| 2020-12-31 | $11.24 Billion | -2.06% |
| 2019-12-31 | $11.48 Billion | +0.37% |
| 2018-12-31 | $11.44 Billion | +1.52% |
| 2017-12-31 | $11.27 Billion | -4.07% |
| 2016-12-31 | $11.74 Billion | +1.31% |
| 2015-12-31 | $11.59 Billion | +2.77% |
| 2014-12-31 | $11.28 Billion | +1.93% |
| 2013-12-31 | $11.07 Billion | +15.66% |
| 2012-12-31 | $9.57 Billion | +8.43% |
| 2011-12-31 | $8.82 Billion | +12.61% |
| 2010-12-31 | $7.84 Billion | +33.93% |
| 2009-12-31 | $5.85 Billion | +30.72% |
| 2008-12-31 | $4.48 Billion | +22.06% |
| 2007-12-31 | $3.67 Billion | +8.08% |
| 2006-12-31 | $3.39 Billion | -10.57% |
| 2005-12-31 | $3.79 Billion | -2.52% |
| 2004-12-31 | $3.89 Billion | -6.78% |
| 2003-12-31 | $4.17 Billion | -1.72% |
| 2002-12-31 | $4.25 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Novozymes AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 200.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $11.03 Billion | 98.72% |
| Common Stock | $125.60 Million | 1.12% |
| Other Comprehensive Income | $134.24 Million | 1.20% |
| Total Equity | $11.18 Billion | 100.00% |
Novozymes AS Competitors by Market Cap
The table below lists competitors of Novozymes AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ashtead Group plc
PINK:ASHTF
|
$20.11 Billion |
|
China Overseas Land Investment
PINK:CAOVY
|
$20.11 Billion |
|
US Foods Holding Corp
NYSE:USFD
|
$20.11 Billion |
|
Novozymes A/S B
PINK:NVZMF
|
$20.13 Billion |
|
CH Robinson Worldwide Inc
NASDAQ:CHRW
|
$20.09 Billion |
|
Legal & General Group Plc
PINK:LGGNY
|
$20.09 Billion |
|
Grupo Cibest S.A.
NYSE:CIB
|
$20.07 Billion |
|
Bank of Jiangsu Co Ltd
SHG:600919
|
$20.05 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Novozymes AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 13,978,000,000 to 11,176,000,000, a change of -2,802,000,000 (-20.0%).
- Net income of 305,800,000 contributed positively to equity growth.
- Dividend payments of 249,800,000 reduced retained earnings.
- New share issuances of 37,800,000 increased equity.
- Other comprehensive income increased equity by 473,243,302.
- Other factors decreased equity by 3,369,043,302.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $305.80 Million | +2.74% |
| Dividends Paid | $249.80 Million | -2.24% |
| Share Issuances | $37.80 Million | +0.34% |
| Other Comprehensive Income | $473.24 Million | +4.23% |
| Other Changes | $-3.37 Billion | -30.15% |
| Total Change | $- | -20.05% |
Book Value vs Market Value Analysis
This analysis compares Novozymes AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.44x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.16x to 1.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $11.20 | $57.81 | x |
| 2003-12-31 | $11.61 | $57.81 | x |
| 2004-12-31 | $10.96 | $57.81 | x |
| 2005-12-31 | $11.22 | $57.81 | x |
| 2006-12-31 | $10.41 | $57.81 | x |
| 2007-12-31 | $11.50 | $57.81 | x |
| 2008-12-31 | $14.17 | $57.81 | x |
| 2009-12-31 | $18.49 | $57.81 | x |
| 2010-12-31 | $24.50 | $57.81 | x |
| 2011-12-31 | $27.53 | $57.81 | x |
| 2012-12-31 | $30.02 | $57.81 | x |
| 2013-12-31 | $34.83 | $57.81 | x |
| 2014-12-31 | $35.77 | $57.81 | x |
| 2015-12-31 | $37.43 | $57.81 | x |
| 2016-12-31 | $38.70 | $57.81 | x |
| 2017-12-31 | $37.87 | $57.81 | x |
| 2018-12-31 | $39.08 | $57.81 | x |
| 2019-12-31 | $40.02 | $57.81 | x |
| 2020-12-31 | $39.83 | $57.81 | x |
| 2021-12-31 | $42.20 | $57.81 | x |
| 2022-12-31 | $49.64 | $57.81 | x |
| 2023-12-31 | $50.28 | $57.81 | x |
| 2024-12-31 | $40.22 | $57.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Novozymes AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.98%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.36x
- Recent ROE (2.74%) is below the historical average (22.55%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 15.93% | 11.47% | 0.68x | 2.06x | $240.80 Million |
| 2003 | 17.87% | 12.67% | 0.76x | 1.86x | $323.70 Million |
| 2004 | 20.72% | 13.16% | 0.84x | 1.86x | $410.20 Million |
| 2005 | 22.89% | 13.71% | 0.86x | 1.94x | $484.90 Million |
| 2006 | 27.12% | 13.39% | 0.85x | 2.37x | $575.10 Million |
| 2007 | 28.49% | 14.01% | 0.84x | 2.43x | $676.30 Million |
| 2008 | 23.78% | 13.04% | 0.82x | 2.22x | $615.50 Million |
| 2009 | 20.48% | 14.13% | 0.78x | 1.87x | $610.90 Million |
| 2010 | 20.63% | 16.60% | 0.77x | 1.61x | $831.60 Million |
| 2011 | 20.75% | 17.39% | 0.76x | 1.57x | $947.10 Million |
| 2012 | 21.09% | 17.94% | 0.74x | 1.58x | $1.06 Billion |
| 2013 | 19.90% | 18.73% | 0.71x | 1.49x | $1.09 Billion |
| 2014 | 22.42% | 20.27% | 0.68x | 1.64x | $1.40 Billion |
| 2015 | 24.38% | 20.16% | 0.79x | 1.54x | $1.67 Billion |
| 2016 | 26.00% | 21.57% | 0.76x | 1.59x | $1.88 Billion |
| 2017 | 27.71% | 21.46% | 0.79x | 1.63x | $1.99 Billion |
| 2018 | 28.24% | 22.42% | 0.73x | 1.72x | $2.08 Billion |
| 2019 | 27.50% | 21.94% | 0.70x | 1.78x | $2.01 Billion |
| 2020 | 25.15% | 20.16% | 0.68x | 1.83x | $1.70 Billion |
| 2021 | 26.60% | 21.04% | 0.60x | 2.09x | $1.96 Billion |
| 2022 | 26.57% | 20.94% | 0.63x | 2.02x | $2.29 Billion |
| 2023 | 21.63% | 16.89% | 0.63x | 2.03x | $1.63 Billion |
| 2024 | 2.74% | 7.98% | 0.25x | 1.36x | $-811.80 Million |
Industry Comparison
This section compares Novozymes AS's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $6,152,730,030
- Average return on equity (ROE) among peers: 7.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Novozymes AS (NVZMY) | $10.78 Billion | 15.93% | 0.52x | $20.10 Billion |
| AirBoss of America Corp (ABSSF) | $125.98 Million | 8.11% | 0.98x | $57.06 Million |
| Asia Carbon Industries Inc (ACRB) | $35.57 Million | 18.14% | 0.12x | $0.99 |
| Aimia Inc (AIMFF) | $-294.90 Million | 0.00% | 0.00x | $103.68 Million |
| L'Air Liquide S.A (AIQUF) | $5.54 Billion | 13.10% | 0.99x | $107.70 Billion |
| Akzo Nobel N.V (AKZOF) | $5.64 Billion | 14.71% | 1.46x | $9.73 Billion |
| Albemarle Corp (ALB) | $4.47 Billion | 8.41% | 1.34x | $19.07 Billion |
| ALPEK S.A.B. de C.V (ALPKF) | $45.06 Billion | 14.66% | 1.28x | $214.40 Million |
| Altech Batteries Limited (ALTHF) | $68.56 Million | -5.13% | 0.13x | $27.89 Million |
| Arcadium Lithium plc (ALTM) | $795.40 Million | 0.08% | 0.51x | $6.26 Billion |
| Alto Ingredients Inc (ALTO) | $94.90 Million | -0.82% | 1.54x | $212.84 Million |